ALBERT B SABIN VACCINE INSTITUTE INC
2175 K Street NW No 400, Washington, DC 20037 www.sabin.org

---

Organizations Filed Purposes: To make vaccines more accessible, enable innovation and expand immunization.

Vaccine Access and Uptake:Despite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by routine immunization. Sabin works with key decision makers and immunization experts at the country and global level to build resilient, sustainable national immunization programs to reach every child.Sabin is an adviser, a convener and a catalyst of systemic change, bringing together researchers, national government officials and immunization specialists at all levels to support the introduction and expansion of new and under-utilized vaccines. In order to make informed decisions about vaccine introduction and implementation, countries require high-quality information and evidence. Sabin supports surveillance programs and conducts research to generate essential epidemiological data for well-designed and efficiently implemented immunization programs. By establishing and sharing best practices, we help countries evaluate and streamline vaccine introduction and scale-up.Collaboration across continents and sectors is critical to extend the benefits of immunization around the globe. Through our international scientific meetings, Sabin fosters dialogue between global health leaders, researchers and implementers to unify global efforts to accelerate access to new and under-utilized vaccines.

Vaccine Knowledge and Innovation:The immunization landscape is constantly evolving. Immunization professionals are faced with the challenge of staying up-to-date on new vaccines, changing policies and recommendations, and developments in vaccine science, while the general public is inundated with information, making it difficult to discern truth from fiction.Sabin drives meaningful, well-informed conversations on emerging and established issues across the field of immunization and provides training and education on the latest in vaccine science and policy to immunization professionals, policymakers and journalists, among others.Sabin fosters a global community that enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts.Sabin works to shape the vaccine conversation by amplifying reliable information on vaccines. We work to dispel misinformation, understand the social drivers of vaccination decisions through research, and understand the role of social media on vaccine confidence. We serve as a leading voice on critical issues in global immunization, including vaccine confidence, vaccine safety and global health innovation. We also work to drive more effective, accurate media coverage on vaccines by equipping journalists and health professionals with the latest information on disease burden and immunization. Sabin drives vaccine innovation by bringing together big thinkers from various industries to accelerate the development of a universal influenza vaccine.

Vaccine Research and Development:The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's R&D strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.Ebola has taken the lives of more than 13,000 people in recent years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is developing vaccines based on technology for three clinical-stage candidate vaccines licensed from GSK. The agreement involves prophylactic candidate vaccines to protect against Ebola Zaire, Ebola Sudan and Marburg virus, all based on GSK's proprietary ChAd3 platform. In an additional agreement, Sabin is partnering with the Vaccine Research Center at the National Institute of Allergy and Infectious Disease to continue development of these vaccines.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202032209349300818_public.xml